Cinqair (reslizumab) / Merck (MSD), UCB, Teva - LARVOL DELTA

Dose-Response and Time-Course Dynamics of Biologics in Eosinophilic Esophagitis: A Model-Based Network Meta-Analysis (ACG 2026) - "Sixteen trial arms across seven classes (dupilumab, cendakimab, mepolizumab, budesonide orodispersible tablet, fluticasone, proton pump inhibitors, and reslizumab) were analyzed. Dupilumab dose-response modeling revealed Emax 88.6%, ED50 1.0 mg, and γ 0.10, indicating near-maximal efficacy at clinical doses with limited gain beyond 100 mg. Increasing from 100 to 300 mg added only 2.3% additional response. Time-course modeling (300 mg weekly) estimated ET50 17.8 weeks, with predicted remission rates of 36% (week 8), 45% (week 12), 62% (week 24), and 80% (week 52), closely matching observed trial data (week 24: 59-60%; week 52: 84.6%)."

Retrospective data • Eosinophilic Esophagitis • Gastrointestinal Disorder • Immunology

Influence of newly initiated biologic therapy on the dose of ICS therapy - Data from the German Asthma Net. (PubMed, J Allergy Clin Immunol Pract) - "ICS reduction was associated with improved patient-reported outcomes without worsening exacerbations, lung function or FeNO."

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Dual Biologic Therapy in Severe Asthma: Real-World Experience at Hospital Clínic de Barcelona (ERS 2026) - "Prior biologics included omalizumab, mepolizumab, benralizumab, reslizumab, and dupilumab...Among the 5 evaluable patients: median annualized exacerbations decreased from 3.0 to 0.5/year; median ACT improved from 18 to 21 points; mean FEV₁ increased 240 mL; 4/5 reduced/discontinued systemic corticosteroids (median 7.5 to 2.5 mg prednisone daily)... Dual therapy with mepolizumab and dupilumab or omalizumab showed clinical benefit in selected patients with severe refractory asthma, particularly those with EGPA, nasal polyposis, and atopic dermatitis. The combination was well-tolerated with improvements in asthma exacerbations, lung function, and corticosteroid-sparing."

Clinical • Real-world • Real-world evidence • Asthma • Atopic Dermatitis • Chronic Rhinosinusitis With Nasal Polyps • Dermatitis • Eosinophilia • Immunology • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases

No increase of OCS after real-world dosing interval extension of biologics in severe asthma in the Dutch RAPSODI registry (ERS 2026) - "RESULTS Of 1603 biologic-treated patients, 69 extended their dosing interval and had available pharmacy data (30% omalizumab, 20% mepolizumab, 13% reslizumab, 10% benralizumab, 26% dupilumab). No differences were observed in total OCS use or OCS courses between these groups. CONCLUSION In this real-world cohort, biologic dosing interval extension was not associated with increased OCS use, supporting its safety in selected well-controlled severe asthma patients."

Clinical • Real-world • Real-world evidence • Asthma • Immunology • Respiratory Diseases

Late Breaking Abstract - Digital spacer monitoring of inhaler adherence and technique to understand treatment response in biologic-treated severe asthma (ERS 2026) - P | "Biologics included dupilumab (n=11), benralizumab (9), mepolizumab (6), tezepelumab (4), omalizumab (1), and reslizumab (1). Median TAI score (49 [IQR 48–50]), blood eosinophils (<300 cells/µL), and daily OCS use (3/32) were unchanged. Conclusion Digital spacer monitoring revealed poor and variable adherence and inhaler technique in biologic-treated severe asthma, potentially contributing to ongoing disease activity (e.g. OCS use)."

Adherence • Late-breaking abstract • Asthma • Immunology • Respiratory Diseases

Blood transcriptomic signature for biological therapy in severe asthma (ERS 2026) - " We included 17 patients with SUA treated with Benralizumab, Mepolizumab, or Reslizumab. The responder patients with SUA treated with BT show a differential gene expression pattern indicating the participation of multiple pathways involved in inflammation and immunity. The six identified genes could contribute to the development of biomarkers to individualise the therapy of severe asthma."

Asthma • Immunology • Inflammation • Respiratory Diseases • CCR3 • SLC29A1

Comparative Efficacy of Anti-interleukin 5/5Rα Biologics in Severe Asthma Stratified by Blood Eosinophil Count: A Systematic Review and Network Meta-analysis (ERS 2026) - "We aim to compare benralizumab, mepolizumab and reslizumab efficacy across subgroups stratified by blood eosinophils counts (Eos) and serum immunoglobulin-E levels (IgE). In severe asthma patients with Eos <150 cells/μL, benralizumab and mepolizumab reduced AER but did not significantly improve preFEV₁. Within the intermediate eosinophil range (150–299 cells/μL), benralizumab , but not mepolizumab, significantly reduced AER. IgE did not influence treatment outcomes."

Retrospective data • Review • Asthma • Immunology • Inflammation • Respiratory Diseases • IL5

New perspectives in the treatment of chronic eosinophilic pneumonia in the era of targeted therapies. (PubMed, Front Immunol) - "This narrative review aims to summarize the available evidence on the effectiveness and safety of anti-IL-5 biologic therapies (mepolizumab, reslizumab, and benralizumab) in the management of CEP and as steroid-sparing strategies, with particular focus on their role in relapse prevention, which occurs in nearly 50% of cases during systemic corticosteroid tapering. Anti-IL-5 biologics represent a promising therapeutic option for patients with relapsing or corticosteroid-dependent CEP. Despite encouraging results, larger prospective studies are needed to better define their role in the long-term management of this disease."

Clinical • Journal • Review • Cough • Diabetes • Eosinophilia • Glaucoma • Infectious Disease • Inflammation • Metabolic Disorders • Ophthalmology • Osteoporosis • Pneumonia • Pulmonary Disease • Respiratory Diseases • Rheumatology • CCL11 • IL5

Biologic therapies targeting type 2 inflammation in NSAID-exacerbated respiratory disease. (PubMed, Front Immunol) - "In this review, we summarize current evidence on the efficacy and mechanisms of action of approved biologic therapies, including omalizumab, anti-IL-5/IL-5Rα agents (mepolizumab, reslizumab, depemokimab, benralizumab), dupilumab and tezepelumab, with a particular focus on their effects on sinonasal disease, asthma control, aspirin tolerance, and patient-reported outcomes. We further discuss emerging concepts of personalized and integrated treatment strategies combining biologics, endoscopic sinus surgery, and aspirin desensitization. Finally, we highlight unmet needs, potential biomarkers and future research directions aimed at optimizing treatment selection and improving long-term disease control in N-ERD."

Journal • Review • Asthma • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Inflammation • Nasal Polyps • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases • Sinusitis • IL5

Real-world disease burden, patient journey and treatment patterns in eosinophilic granulomatosis with polyangiitis in Europe and the USA. (PubMed, EULAR Rheumatol Open) - "Glucocorticoids were the most prescribed therapies (79%), and the use of interleukin-5-/receptor alpha-targeted therapies was low (21% mepolizumab, 7% benralizumab, <1% reslizumab). EGPA is associated with a considerable disease burden. Increased disease awareness to facilitate prompt diagnosis and treatment and optimised management to achieve remission and enhance patients' HRQoL are needed."

Journal • Real-world evidence • Eosinophilic Granulomatosis With Polyangiitis • Immunology • Langerhans Cell Histiocytosis • Rare Diseases • Vasculitis • IL5

Characteristics of severe asthma patients with biologic treatment in the Swedish National Airway Register. (PubMed, Eur Clin Respir J) - "Patients with ongoing treatment with mepolizumab, benralizumab, reslizumab, dupilumab or tezepelumab and registered in SNAR between 2016 and 2024 were included. However, variation in inclusion and follow-up limits longitudinal interpretation. More standardized registration, particularly at treatment initiation, would strengthen SNAR's role in national monitoring, quality improvement and future research."

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Biologic Therapy and Aspirin Reactivity in AERD: A Scoping Review. (PubMed, J Allergy Clin Immunol Pract) - "There are limited studies in the literature about biologic use specifically on COX-1 reactivity in AERD. The studies that have been completed are relatively small and predominantly non-randomized. Larger studies are needed to provide a more precise measurement of the effect of the various therapies on aspirin reactivity in AERD. Methods to predict resolution of aspirin reactivity in AERD are needed to appropriately counsel patients. Given the widespread use of biologic therapies in AERD, the lack of understanding regarding residual COX-1 reactivity even when the AERD is otherwise controlled presents an urgent future research need."

Journal • Inflammation • Respiratory Diseases

Efficacy and Safety of Biologic Therapies for Uncontrolled Asthma: An Overview of Systematic Reviews. (PubMed, Pediatr Pulmonol) - "The available evidence suggests that biologic therapies may be effective and generally safe options for uncontrolled asthma, although the methodological quality of most included reviews was critically low. These findings support individualized treatment guided by biomarkers and clinical characteristics and highlight the need for standardized, methodologically rigorous future studies."

Journal • Review • Asthma • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

pIgR Stem Zone-Targeted Nanobodies as Apical-to-Basolateral Carriers for Inhaled Biologic Delivery Across Mucosal Barriers. (PubMed, Antibodies (Basel)) - "These findings suggest that stem domain-specific binding may facilitate transport across the mucosal barrier while preserving native receptor physiology, offering a potential strategy for effective transmucosal delivery of biologics."

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases • IL5

Efficacy and Safety of IL-4Rα and IL-5/IL-5R Targeted Biologic Therapies in Type 2 Inflammatory Airway Diseases: A Systematic Review and Meta-Analysis. (PubMed, J Clin Med) - " We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) evaluating dupilumab, mepolizumab, benralizumab, or reslizumab in patients with type 2 inflammatory asthma and/or CRSwNP. IL-4Rα inhibition shows favorable upper-airway outcomes in CRSwNP with asthma, but head-to-head trials are needed to clarify its comparative efficacy relative to IL-5/IL-5R-targeted therapies. Emerging research directions are shifting toward upstream epithelial alarmin antibodies."

Journal • Retrospective data • Review • Asthma • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Inflammation • Nasal Polyps • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases • Sinusitis • IL5 • TSLP

Therapeutic Efficacy of Anti-Interleukin-5 Monoclonal Antibodies in Kimura Disease: A Systematic Review. (PubMed, Cureus) - "This study aims to investigate the efficacy of benralizumab, reslizumab, and mepolizumab in the treatment of KD. Current evidence is limited by the reliance on small, heterogeneous case series. Multicenter prospective registries or international collaborative cohorts are required to validate these findings and standardize dosing regimens."

Journal • Review • Eosinophilia • Oncology • Pain • IL5

A Narrative Review of Biologic Therapies for Type 2 Inflammation in Severe Asthma and Eosinophilic Chronic Obstructive Pulmonary Disease (COPD): Mechanisms, Efficacy, and Safety. (PubMed, Cureus) - "Currently approved biologics target immunoglobulin E (omalizumab), interleukin (IL)-5 or its receptor (mepolizumab, reslizumab, depemokimab, and benralizumab), IL-4 receptor α (dupilumab), and thymic stromal lymphopoietin (tezepelumab). These agents have demonstrated substantial reductions in exacerbation rates, improved lung function, corticosteroid-sparing effects, and enhanced quality of life across diverse patient populations. This review examines the mechanisms of action, clinical efficacy, safety profiles, and optimal patient selection strategies for biologic therapies in severe asthma and eosinophilic COPD."

Journal • Review • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases • IL4 • TSLP

Biological functions and clinical efficacy of IL-5/IL-5Rα-targeted therapies across eosinophilia-associated diseases. (PubMed, Front Immunol) - "Four biologics currently target this pathway in clinical practice: mepolizumab, reslizumab, and depemokimab bind soluble IL-5, whereas benralizumab targets IL-5Rα and induces antibody-dependent cellular cytotoxicity. Safety data from randomized trials, extension studies, real-world cohorts, and meta-analyses are generally reassuring, with most adverse events being mild to moderate and no consistent major safety signal. This review synthesizes current understanding of IL-5 biology, critically evaluates the clinical trial evidence for IL-5/IL-5Ra-targeted biologics across major eosinophilia-associated diseases, and highlights remaining evidence gaps and future directions."

Journal • Review • Asthma • Chronic Rhinosinusitis With Nasal Polyps • Eosinophilia • Eosinophilic Granulomatosis With Polyangiitis • Hypereosinophilic Syndrome • Immunology • Langerhans Cell Histiocytosis • Nasal Polyps • Otorhinolaryngology • Pulmonary Disease • Rare Diseases • Respiratory Diseases • Sinusitis • Vasculitis • IL5

Modern approaches in asthma management: Revolutionizing severe asthma treatment with biologics. (PubMed, J Pak Med Assoc) - "Five new biologics have revolutionised severe asthma therapy apart from omalizumab, which are mepolizumab, benralizumab, reslizumab, dupilumab and tezepelumab. For both rescue and maintenance therapies, the available guidelines prove the efficacy of inhaled corticosteroids and long-acting beta-2 agonists, like formoterol. Future guidelines ought to incorporate phenotype/endotype-focussed management to acquire further precision-directed therapy."

Journal • Review • Asthma • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

The Clinical and Economic Impact of Biologic Agents in Asthma Management: a Systematic Review. (PubMed, Lung) - "Biologic therapies achieve substantial clinical benefits and favorable economic value through healthcare cost offsets. Precision medicine approaches and early response assessment optimize patient selection and clinical outcomes in severe asthma management."

HEOR • Journal • Review • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

The Use of Biomarkers to Justify the Choice of the Proper Biologic Agent for the Treatment of Chronic Rhinosinusitis with Nasal Polyps: A Systematic Review. (PubMed, Medicina (Kaunas)) - "This systematic review aimed to evaluate the available evidence regarding predictive and prognostic biomarkers associated with currently available biologic agents for CRSwNP (omalizumab, dupilumab, mepolizumab, benralizumab, reslizumab, and tezepelumab). Current evidence supports biomarker use primarily for confirming type 2 inflammation rather than guiding biologic selection. Prospective biomarker-driven and head-to-head comparative studies are needed to enable precision medicine approaches in CRSwNP."

Biomarker • Journal • Review • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Inflammation • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis • CCL11 • IL13 • IL4 • IL5 • POSTN

Real-world dosing interval extension of biologics in severe asthma in the Dutch RAPSODI registry: can this be successfully applied? (EAACI 2026) - "Results Among 1603 biologic-treated patients, 102 underwent dosing interval extension (30% omalizumab, 23% mepolizumab, 10% reslizumab, 13% benralizumab, 25% dupilumab). A subset of patients is not able to maintain the extended interval, reflected by an increase in symptoms. These results highlight the potential of personalised dosing and warrant further research to identify predictors of successful interval extension."

Clinical • Real-world • Real-world evidence • Allergy • Immunology

Neoplasm Adverse Events Associated With Anti-Type 2 Biologics: An FAERS Database Pharmacovigilance Analysis Study. (PubMed, Cancer Med) - "This pharmacovigilance study detected neoplasm-related disproportionality signals for anti-Type 2 biologics. Causality cannot be established due to spontaneous reporting limitations. Clinicians should be aware of these disproportionality signals and maintain vigilance during long-term clinical management of patients receiving anti-Type 2 biologic therapy to ensure optimal patient safety."

Adverse events • Journal • Asthma • Breast Cancer • Cutaneous T-cell Lymphoma • Genito-urinary Cancer • Hematological Malignancies • Immunology • Lung Cancer • Lymphoma • Oncology • Prostate Cancer • Pulmonary Disease • Respiratory Diseases • Solid Tumor • T Cell Non-Hodgkin Lymphoma • IL5

Depemokimab reduces asthma exacerbations similarly to other biologics: systematic trial review and indirect treatment comparison. (PubMed, Ann Allergy Asthma Immunol) - "In general, no statistically significant difference was detected between depemokimab and other biologics in terms of AER reduction or safety in severe asthma, including when adjusting for differences across studies in clinically important patient characteristics."

Clinical • Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Circulating 1-methylnicotinamide can predict the treatment response of dupilumab in adult asthma (EAACI 2026) - "Method Baseline plasma samples (N=275) from individuals receiving biologics (dupilumab [n=150], mepolizumab [n=31] and reslizumab [n=42]) or conventional treatment (T2 high conventional [n=25] and T2 low [n=27]) in the Precision Medicine Intervention in Severe Asthma (PRISM) cohort were analyzed using untargeted metabolomics to identify candidate biomarkers. Predictive modeling shows 1-MNA provides stronger discrimination between responders and non-responders than conventional clinical markers. These findings suggest that 1-MNA could support biomarker-guided selection of biologic therapy, although external validation and mechanistic studies are needed to confirm its clinical utility."

Clinical • Immunology